Journal Information
Vol. 41. Issue 9.
Pages 489-492 (September 2005)
Share
Share
Download PDF
More article options
Vol. 41. Issue 9.
Pages 489-492 (September 2005)
Original Articles
Full text access
Lung Transplantation in Cystic Fibrosis: Perioperative Mortality
Visits
3996
J. Padilla
Corresponding author
jpadilla@comv.es

Correspondence: Dr. J. Padilla. Servicio de Cirugía Torácica. Hospital Universitario La Fe. Avda. de Campanar, 21. 46009 Valencia. España
, V. Calvo, C. Jordá, J. Escrivá, J. Cerón, J.C. Peñalver, A. García-Zarza, J. Pastor, E. Blasco
Servicio de Cirugía Torácica, Hospital Universitario La Fe, Valencia, Spain
This item has received
Article information
Objective

To determine the incidence and causes of perioperative mortality following lung transplant for cystic fibrosis.

Patients and methods

We analyzed the cases of 57 patients. Fifty-five patients received double lung transplants, 1 received a heart-double lung transplant, and 1 received a combined double lung and liver transplant. Information related to the organ donor, recipient, lung graft, and early postoperative period was gathered. Perioperative mortality was defined as death resulting from anesthesia or surgery regardless of how many days had passed. The Kaplan-Meier method was used to analyze survival. A Cox logistic regression model was used to determine variables affecting mortality.

Results

Survival was 83.7% at 1 year after transplantation, 77.3% at 2 years, and 66.9% at 5 years. Five (8.7%) patients died as a result of anesthesia or surgery. A ratio of PaO2 to inspired oxygen fraction (FiO2) less than 200 mm Hg in the early postoperative period was observed in 8 (14%) patients. Primary graft failure occurred in 4 patients, due to pneumonia in 2 and to biventricular dysfunction in 2. Three of those patients died. Two patients with PaO2/FiO2 greater than 200 mm Hg died after surgery, 1 from septic shock due to Pseudomonas cepacia and the other from massive cerebral infarction.

PaO2/FiO2 upon admission to the recovery care unit was the only variable significantly associated with perioperative mortality in the logistic regression model (P = .0034).

Conclusions

The only factor significantly related to perioperative mortality in patients receiving transplants for cystic fibrosis was PaO2/FiO2 upon admission to the recovery unit.

Key Words:
Cystic fibrosis
Lung transplant
Perioperative mortality
Objetivo

Conocer la incidencia y las causas de mortalidad perioperatoria en el trasplante pulmonar por fibrosis quística.

Pacientesy métodos

Se ha analizado a 57 pacientes. Se realizaron 55 trasplantes bipulmonares, uno cardiobipulmonar y uno hepatobipulmonar. Se recogieron una serie de datos del donante, del receptor, del injerto pulmonar y del postoperatorio inmediato. Se definió la mortalidad perioperatoria cuando el fallecimiento aconteció como consecuencia del acto anestésico-quirúrgico, independientemente de los días transcurridos. Para determinar qué variables la condicionaron se utilizó el modelo de regresión logística de Cox. La supervivencia se calculó mediante el método de Kaplan-Meier.

Resultados

La supervivencia fue del 83,7% al año del trasplante, del 77,3% a los 2 años y del 66,9% a los 5 años. Cinco pacientes (8,7%) fallecieron en el perioperatorio. En 8 (14%) se objetivó un cociente de presión arterial de oxígeno (PaO2)/fracción inspiratoria de oxígeno (FiO2) inspirado < 200 mmHg en el perioperatorio inmediato y 4 se catalogaron como fracaso primario del injerto, 2 por una neumonía y 2 por disfunción biventricular; 3 de estos pacientes fallecieron. Dos pacientes con un cociente PaO2/FiO2 >200 mmHg fallecieron en el perioperatorio, uno por un shock séptico por Pseudomonas cepacia y otro por un infarto cerebral masivo.

Mediante el análisis de regresión logística, el cociente PaO2/FiO2 al ingresar en la unidad de reanimación fue la única variable que condicionó significativamente la mortalidad perioperatoria (p = 0,0034).

Conclusiones

El cociente PaO2/FiO2 al ingresar en la unidad de reanimación fue la única variable que condicionó significativamente la mortalidad perioperatoria en los pacientes trasplantados por fibrosis quística.

Palabras clave:
Fibrosis quística
Trasplante pulmonary
Mortalidad perioperatoria
Full text is only aviable in PDF
REFERENCES
[1]
Cystic Fibrosis Foundation.
[2]
JD Hosenpud, LE Bennett, BM Keck, EB Edwards, RJ Novick.
Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease.
[3]
M Hertz, D Taylor, EP Trulock, MM Boucek, P Mohacsi, L Edwards, et al.
The Registry of International Society for Heart and Lung Transplantation: nineteenth official report: 2002.
J Heart Lung Transplant, 21 (2002), pp. 950-970
[4]
TM Egan, FC Detterbeck, MR Mill, KK Gott, JB Rea, J McSweeney, et al.
Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group.
Ann Thorac Surg, 66 (1998), pp. 337-346
[5]
LA Vricella, JM Karamichalis, S Ahmad, MC Robbins, RI Whyte, BA Reitz.
Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience.
Ann Thorac Surg, 74 (2002), pp. 13-18
[6]
FJ Gómez, A Planas, P Ussetti, JJ Tejada, A Varela.
Factores pronósticos de morbimortalidad en el postoperatorio inmediato del trasplante pulmonar.
Arch Bronconeumol, 39 (2003), pp. 256-260
[7]
R Lama, A Álvarez, F Santos, J Algar, JL Aranda, C Baamonde, et al.
Long-term results of lung transplantation for cystic fibrosis.
Transplant Proc, 33 (2001), pp. 1624-1625
[8]
F Venuta, EA Rendina, T de Giacomo, G della Rocca, S Quattrucci, CD Vizza, et al.
Improved results with lung transplantation for cystic fibrosis.
Transplant Proc, 33 (2001), pp. 1632-1633
[9]
WHO.
Physical status: the use and interpretation of anthropometry: report of a WHO expert committee.
WHO Tech Rep Ser, 854 (1995), pp. 1-452
[10]
CD Vizza, JP Lynch, LL Ochoa, G Richardson, EP Trulock.
Right and left ventricular dysfunction in patients with severe pulmonary disease.
Chest, 113 (1998), pp. 576-583
[11]
W Plöchl, L Pezawas, O Artemiou, M Grimm, W Klepetko, M Hiesmayr.
Nutritional status, ICU duration and ICU mortality in lung transplant recipient.
Intensive Care Med, 22 (1996), pp. 1179-1185
[12]
AJ Boujoukos, GD Martich, JD Vega, RJ Keenan, BP Griffith.
Reperfusion injury in single-lung transplant recipients with pulmonary hypertension and emphysema.
J Heart Lung Transplant, 16 (1997), pp. 440-448
[13]
GR Bernard, A Artigas, KL Brigham, J Carlet, K Falke, L Hudson, et al.
The American-European Consensus Conference on ARDS.
Am J Respir Crit Care Med, 149 (1994), pp. 818-824
[14]
JD Christie, JE Bavaria, HI Palevsky, L Litzky, NP Blumenthal, LR Kaiser, et al.
Primary graft failure following lung transplantation.
Chest, 114 (1998), pp. 51-60
[15]
C Müller, H Furst, H Reichenspurner, J Briegel, J Groh, B Reichart.
Lung procurement by low-potassium dextran and the effect on preservation injury. Munich Lung Transplant Group.
Transplantation, 68 (1999), pp. 1139-1143
[16]
RC King, RA Oliver, AR Bins, F Rodríguez, RC Kanithanon, TM Daniel, et al.
Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.
Ann Thorac Surg, 69 (2000), pp. 1681-1685
[17]
J Padilla, V Calvo, J Pastor, E Blasco, F París.
Trasplante unipulmonar y fracaso primario del injerto.
Arch Bronconeumol, 38 (2002), pp. 16-20
[18]
J Schulman.
Perioperative mortality and primary graft failure.
Chest, 114 (1998), pp. 7-8
[19]
EP Trulock.
Lung transplantation.
Am J Resp Crit Care Med, 155 (1997), pp. 789-818
[20]
JM Rabanal, R Mons, F Zurbano, I Ruiz, JL Alcíbar, J Ortega.
Edema de reimplantación en el trasplante pulmonar. ¿Isquemia-reperfusión o edema hidrostático?.
Rev Esp Anestesiol Reanim, 48 (2001), pp. 146-150
[21]
AM Padilla, J Padilla.
Estado actual de la preservación pulmonar.
Arch Bronconeumol, 40 (2004), pp. 86-93
[22]
KL Fraser, DE Tullis, Z Sasson, RH Hyland, KS Thornley, PJ Hanly.
Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia.
Chest, 115 (1999), pp. 1321-1328
[23]
CD Vizza, RD Yusen, JP Lynch, F Fedele, AG Patterson, EP Trulock.
Outcome of patients with cystic fibrosis awaiting lung transplantation.
Am J Respir Cell Mol Biol, 162 (2000), pp. 189-225
[24]
CD Vizza, S Sciomer, G della Rocca, C Di Roma, C Iacoboni, F Venuta, et al.
Usefulness of 2D echo Doppler in the preoperative assessment of cystic fibrosis patients who are candidates for lung transplantation.
Transplant Proc, 33 (2001), pp. 1628-1629
[25]
H Mal, M Dehoux, C Sleiman, J Boczkowski, G Lesèche, R Pariente, et al.
Early release of proinflammatory cytokines after lung transplantation.
Chest, 113 (1998), pp. 645-651
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?